Chair: R Rizzoli

Members: E Biver, R Blank, JJ Body, ML Brandi, C Campusano, J Cannata-Andia, M Chakhtoura, C Confavreux, P Ebeling, G El Hajj Fuleihan, A El Maghraoui, J Foldes, C Glüer, G Guglielmi, P Hadji, G Holzer, D Kendler, N Napoli, T de Villiers.

To define and assess the effects on bones following a cancer or cancer treatment.

• Discontinuation of denosumab in women with non-metastatic breast cancer
• Bone side effects of anticancer drugs
• Monoclonal gammopathy of undetermined significance (MGUS) and Bone Fragility and fractures
• Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in premenopausal women with hormone-sensitive breast cancer
• Bone health in patients with non-metastatic prostate cancer

1. Teissonnière, M., et a. Bone Effects of Anti-Cancer Treatments in 2024. Calcif Tissue Int 116, 54 (2025).
2. Kendler, D.L., et al. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.
   J Bone Oncol . 2021 23;28:100361. 
3. Marcucci, G., et al., Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Ann Oncol, 2019. 30(6): p. 908-920.
4. Kendler, D.L., et al., Bone management in hematologic stem cell transplant recipients. Osteoporos Int, 2018. 29(12): p. 2597-2610.
5. Cianferotti, L., et al., The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 2017. 8(43): p. 75646-75663.
6. Hadji, P., et al., Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
   J Bone Oncol, 2017. 7: p. 1-12.
7. Rizzoli, R., et al., Cancer-associated bone disease. Osteoporos Int, 2013. 24(12): p. 2929-53.